Brief: Immutep Discontinues Phase III Tacti-004 Study In Non-Small Cell Lung Cancer
08/04/2026 02:24
April 8 (Reuters) - Immutep Ltd IMM.AX: DISCONTINUES PHASE III TACTI-004 STUDY IN NON-SMALL CELL LUNG CANCER ESTIMATES REVIEW PROCESS COULD EXTEND INTO Q3 2026 Further company coverage: IMM.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Immutep
See all newsBrief: Immutep Receives NASDAQ Notice Of Minimum Bid Price Non-Compliance
Australia's Immutep extends gain on FDA orphan drug status for cancer drug
Brief: Immutep Ltd Says FDA Granted Orphan Drug Designation For Eftilagimod alfa In Soft Tissue Sarcoma
Brief: Immutep Discontinues Phase III Tacti-004 Study In Non-Small Cell Lung Cancer
Brief: Dr Reddy's Says IDMC Recommends Discontinuation Of TACTI-004 Phase III Trial After Interim Futility Analysis